FDA Warns Novartis, Shire On Misbranding
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire pulls Fosrenol promos, calling them an “an unfortunate error.”
You may also be interested in...
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks
Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.